Shares of Pluristem Therapeutics Inc. PSTI, a bio-therapeutics company focusing on the treatment of multiple ischemic and inflammatory conditions, were trading higher by more than 7 percent early Wednesday morning after the company announced it was granted two key cell therapy patents.
Pluristem Therapeutics said that the Japan Patent Office granted the company two patents regarding its products. The first patent addresses its core technology of three-dimensional expansion methods for producing therapeutic cell products derived from placental or fat cells. The second patent relates to the of placenta-derived cells grown with this 3D technology to treat disorders of the hematopoietic system.
The company added that it continues to strengthen its IP position to support potential partnerships in Japan for the development and commercialization of its PLAcental eXpanded (PLX) cells.
"These latest patent grants in Japan fortify our intellectual property position globally, and specifically in the Japanese market, where we are in active negotiations with potential pharmaceutical partners," stated Pluristem Chairman and CEO Zami Aberman. "Our proprietary process and technology for growing placenta-derived cells within a 3D microenvironment make large scale, cost effective cell therapy production a reality, and IP protection of these methods in Japan is a key asset. The use of these cells to treat disorders of the hematopoietic system is an important indication for PLX cells that is now protected in Japan."
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
